Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine

Abstract

The strengthening of the robustness of discovery technologies, particularly in genomics, proteomics and metabolomics, has been followed by intense discussions on establishing well-defined evaluation procedures for the identified biomarker to ultimately allow the clinical validation and then the clinical use of some of these biomarkers.